| abstract |
The invention relates to the use of sodium 4-phenylbutyrate (4 PBA) in the production of a medicament used to treat cognitive disorders in dementias with tauopathies. Treatment with 4 PBA improves the cognitive deficit of a classic murine Alzheimer's disease (AD) model (Tg 2576), reducing a characteristic AD marker, such as phosphorilated Tau, and increasing the synthesis of some marker proteins for synaptic plasticity, such as GIuR1 and PSD95. The reduction of stress in the endoplasmic reticulum, manifested by an increase in the GRP78 protein, constitutes a mechanism for mediating the therapeutic effect. In addition, the effect thereof as an inhibitor of the deacetylation of histones and the involvement thereof in the remodelling of the chromatin facilitates the protein synthesis processes, improving the synaptic plasticity. |